Related references
Note: Only part of the references are listed.Global quantitative assessment of the colorectal polyp burden in familial adenomatous polyposis by using a Web-based tool
Patrick M. Lynch et al.
GASTROINTESTINAL ENDOSCOPY (2013)
Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial
Frank L. Meyskens et al.
CANCER PREVENTION RESEARCH (2008)
Guidelines for the clinical management of familial adenomatous polyposis (FAP)
H. F. A. Vasen et al.
GUT (2008)
A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas
John A. Baron et al.
GASTROENTEROLOGY (2006)
Celecoxib for the prevention of colorectal adenomatous polyps
Nadir Arber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Celecoxib for the prevention of sporadic colorectal adenomas
Monica M. Bertagnolli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
RS Bresalier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention
SD Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Rofecoxib reduces polyp recurrence in familial polyposis
A Hallak et al.
DIGESTIVE DISEASES AND SCIENCES (2003)
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
G Steinbach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
